We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ISRG Shares Rise as FDA Clears AI Integration for Ion Platform
Read MoreHide Full Article
Key Takeaways
Intuitive Surgical gains FDA clearance for AI integration in its Ion Endoluminal System.
New software adds real-time navigation and advanced imaging to improve biopsy accuracy.
Upgrade strengthens ISRG's edge in minimally invasive diagnostics and early cancer detection.
Intuitive Surgical (ISRG - Free Report) recently received FDA clearance for software advancements in its Ion Endoluminal System, marking a key step forward in AI-driven lung care. The new release integrates artificial intelligence across the Ion platform’s navigation workflow and adds advanced imaging capabilities, enhancing the accuracy and efficiency of lung biopsy procedures.
The upgrade enables real-time navigation adjustments and broadens access to imaging options, helping physicians better reach and sample hard-to-access lung nodules. This development strengthens Intuitive Surgical’s position in the rapidly expanding minimally invasive diagnostics market and underscores its continued focus on innovation to support early cancer detection and improved patient outcomes.
Likely Trend of ISRG Stock Following the News
Following the announcement, the company's shares gained 1.6% until yesterday’s closing. Shares have lost 14.1% in the year-to-date period compared with the industry’s 8.7% decline. The S&P 500 has gained 15% in the same time frame.
This FDA-cleared upgrade is likely to boost ISRG’s business by expanding the clinical utility and the adoption of its Ion Endoluminal System, opening new revenue opportunities in lung diagnostics. By integrating AI and advanced imaging, Intuitive Surgical enhances procedural accuracy and efficiency, key factors that drive hospital demand and recurring instrument usage. The move also strengthens its ecosystem advantage, positioning ISRG to capture a greater share in early-stage cancer care while reinforcing its reputation as a leader in minimally invasive innovation.
ISRG currently has a market capitalization of $158.1 billion. It has an earnings yield of 1.45%, higher than the industry’s negative 1.85%. In the last reported quarter, ISRG delivered an earnings surprise of 14.1%.
Image Source: Zacks Investment Research
More on the News
The latest Ion software release incorporates artificial intelligence into every stage of the platform’s navigation workflow, marking a significant leap in precision and efficiency for lung biopsies. One of the biggest challenges in these procedures is CT-to-body divergence, where the nodule’s location shifts during the operation compared to the pre-procedure scan. Ion now uses AI-driven computer vision alongside its shape-sensing technology to automatically detect these changes and adjust the navigation path in real time. This “GPS-like” capability could significantly improve targeting accuracy, reduce manual intervention, and enable physicians to deliver faster and more confident diagnoses.
Beyond navigation, Intuitive Surgical is expanding access to advanced imaging with integrated tomosynthesis, a feature that allows real-time 3D-like imaging using a standard 2D C-arm. This innovation offers hospitals greater flexibility by introducing enhanced imaging capabilities to settings where high-end imaging systems may not be readily available. It allows clinicians to tailor workflows to each patient’s needs, potentially improving diagnostic yield and procedural safety. This diversification of imaging capabilities supports Intuitive Surgical’s broader strategy of making its systems adaptable across various hospital environments, from top-tier research centers to regional facilities.
Intuitive Surgical plans to roll out these software advancements through a limited launch to collect real-world insights before expanding across the United States in 2026. With more than 900 Ion systems already installed globally and over 100 related studies published, the company is building a strong evidence base to support adoption and reimbursement discussions. These upgrades not only enhance the Ion system’s competitiveness but also deepen Intuitive Surgical’s presence in lung cancer diagnosis, one of the world’s largest and fastest-growing healthcare challenges. For investors, this continued momentum in AI integration and clinical expansion highlights ISRG’s disciplined innovation engine and long-term growth visibility.
Favorable Industry Prospects for ISRG
Per a report by Grand View Research, the global surgical robots market size was estimated at $4.31 billion in 2024 and is projected to reach $7.42 billion by 2030, registering a CAGR of 9.42% from 2025 to 2030.
Industry growth is driven by technological innovation, increasing investments from global and regional players, as well as a rise in chronic conditions and joint replacement procedures.
Masimo shares have lost 10.4% so far this year compared with the industry’s 7.4% decline. Estimates for the company’s 2025 earnings per share have increased 1.3% to $5.30 in the past 30 days.
MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.8%. In the last reported quarter, it posted an earnings surprise of 8.1%.
Estimates for Merit Medical’s 2025 earnings per share have increased 0.8% to $3.63 in the past 60 days. Shares of the company have lost 13.8% so far this year against the industry’s 1.1% growth.
MMSI’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.92%. In the last reported quarter, it delivered an earnings surprise of 17.44%.
Estimates for West Pharmaceutical’s 2025 earnings per share have increased 1.2% to $6.74 in the past 60 days. Shares of the company have lost 18.2% so far this year against the industry’s 1% growth.
WST’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.81%. In the last reported quarter, it delivered an earnings surprise of 21.85%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
ISRG Shares Rise as FDA Clears AI Integration for Ion Platform
Key Takeaways
Intuitive Surgical (ISRG - Free Report) recently received FDA clearance for software advancements in its Ion Endoluminal System, marking a key step forward in AI-driven lung care. The new release integrates artificial intelligence across the Ion platform’s navigation workflow and adds advanced imaging capabilities, enhancing the accuracy and efficiency of lung biopsy procedures.
The upgrade enables real-time navigation adjustments and broadens access to imaging options, helping physicians better reach and sample hard-to-access lung nodules. This development strengthens Intuitive Surgical’s position in the rapidly expanding minimally invasive diagnostics market and underscores its continued focus on innovation to support early cancer detection and improved patient outcomes.
Likely Trend of ISRG Stock Following the News
Following the announcement, the company's shares gained 1.6% until yesterday’s closing. Shares have lost 14.1% in the year-to-date period compared with the industry’s 8.7% decline. The S&P 500 has gained 15% in the same time frame.
This FDA-cleared upgrade is likely to boost ISRG’s business by expanding the clinical utility and the adoption of its Ion Endoluminal System, opening new revenue opportunities in lung diagnostics. By integrating AI and advanced imaging, Intuitive Surgical enhances procedural accuracy and efficiency, key factors that drive hospital demand and recurring instrument usage. The move also strengthens its ecosystem advantage, positioning ISRG to capture a greater share in early-stage cancer care while reinforcing its reputation as a leader in minimally invasive innovation.
ISRG currently has a market capitalization of $158.1 billion. It has an earnings yield of 1.45%, higher than the industry’s negative 1.85%. In the last reported quarter, ISRG delivered an earnings surprise of 14.1%.
Image Source: Zacks Investment Research
More on the News
The latest Ion software release incorporates artificial intelligence into every stage of the platform’s navigation workflow, marking a significant leap in precision and efficiency for lung biopsies. One of the biggest challenges in these procedures is CT-to-body divergence, where the nodule’s location shifts during the operation compared to the pre-procedure scan. Ion now uses AI-driven computer vision alongside its shape-sensing technology to automatically detect these changes and adjust the navigation path in real time. This “GPS-like” capability could significantly improve targeting accuracy, reduce manual intervention, and enable physicians to deliver faster and more confident diagnoses.
Beyond navigation, Intuitive Surgical is expanding access to advanced imaging with integrated tomosynthesis, a feature that allows real-time 3D-like imaging using a standard 2D C-arm. This innovation offers hospitals greater flexibility by introducing enhanced imaging capabilities to settings where high-end imaging systems may not be readily available. It allows clinicians to tailor workflows to each patient’s needs, potentially improving diagnostic yield and procedural safety. This diversification of imaging capabilities supports Intuitive Surgical’s broader strategy of making its systems adaptable across various hospital environments, from top-tier research centers to regional facilities.
Intuitive Surgical plans to roll out these software advancements through a limited launch to collect real-world insights before expanding across the United States in 2026. With more than 900 Ion systems already installed globally and over 100 related studies published, the company is building a strong evidence base to support adoption and reimbursement discussions. These upgrades not only enhance the Ion system’s competitiveness but also deepen Intuitive Surgical’s presence in lung cancer diagnosis, one of the world’s largest and fastest-growing healthcare challenges. For investors, this continued momentum in AI integration and clinical expansion highlights ISRG’s disciplined innovation engine and long-term growth visibility.
Favorable Industry Prospects for ISRG
Per a report by Grand View Research, the global surgical robots market size was estimated at $4.31 billion in 2024 and is projected to reach $7.42 billion by 2030, registering a CAGR of 9.42% from 2025 to 2030.
Industry growth is driven by technological innovation, increasing investments from global and regional players, as well as a rise in chronic conditions and joint replacement procedures.
ISRG’s Zacks Rank & Key Picks
Currently, ISRG carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Masimo (MASI - Free Report) , Merit Medical System (MMSI - Free Report) and West Pharmaceutical Services (WST - Free Report) . Each stock presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Masimo shares have lost 10.4% so far this year compared with the industry’s 7.4% decline. Estimates for the company’s 2025 earnings per share have increased 1.3% to $5.30 in the past 30 days.
MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.8%. In the last reported quarter, it posted an earnings surprise of 8.1%.
Estimates for Merit Medical’s 2025 earnings per share have increased 0.8% to $3.63 in the past 60 days. Shares of the company have lost 13.8% so far this year against the industry’s 1.1% growth.
MMSI’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.92%. In the last reported quarter, it delivered an earnings surprise of 17.44%.
Estimates for West Pharmaceutical’s 2025 earnings per share have increased 1.2% to $6.74 in the past 60 days. Shares of the company have lost 18.2% so far this year against the industry’s 1% growth.
WST’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.81%. In the last reported quarter, it delivered an earnings surprise of 21.85%.